Ikechukwu Achebe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ikechukwu Achebe has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Jennifer Chiagoziem Asotibe
Cook County Hospital, Chicago, IL, USA
10 shared publications - Hafeez Shaka
Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, USA
6 shared publications - Chimezie Mbachi
Internal Medicine, John H. Stroger, Jr. Hospital of Cook County, Chicago, USA
3 shared publications - Chun-Wei Pan
Department of Internal Medicine, John H. Stroger Hospital of Cook County, Chicago, IL
2 shared publications - Emmanuel Palomera-Tejeda
Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, Texas, USA; Department of Gastroenterology, Baylor St Luke's Medical Center, Houston, Texas, USA
2 shared publications Garima Pudasaini
Cook County Hospital, Chicago, IL, USA
2 shared publications
Latest Publications
- Open Access
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A449
Rates and Predictors of 30-Day Readmission in Adults with Type 1 Diabetes Hospitalized for Diabetic Ketoacidosis in the US: A Nationwide Study
Introduction: Diabetic ketoacidosis (DKA) is an endocrinological emergency that may be associated with inpatient mortality. This hyperglycemic state is more common in type 1 diabetics (T1DM) as insulin deficiency promotes lipolysis and ketogenesis. Due to the difference in epidemiologic and comorbidity profiles between T1DM and other types of diabetes, it is important to investigate factors affecting this unique group. This study assessed the rate and predictors of readmission in adults with T1DM hospitalized for DKA. Methods: The National Readmission Database for 2017 was searched for hospitalizations involving persons 18 years or older with T1DM who were principally admitted for DKA from January 1 to November 30, 2017. Patients admitted electively or traumatic admissions were excluded from the analysis. Outcomes assessed were 30-day readmission rates, mortality, length of stay (LOS) and hospitalization charges (THC). Multivariate cox regression model was adapted to identify independent predictors of readmission. Results: A total of 91,625 hospitalizations involved adult with T1DM for DKA with 91,401 discharged alive. Of the patients discharged alive, the rate of 30-day readmission was 20.2%, involving 18,553 patients. A majority of patients had a principal readmission for DKA. Compared to the index admission, a 30-day readmission was associated with over two times the mortality rate (Risk ratio 2.06, 95% CI: 1.74 - 2.43, p<0.001). Readmission was associated with increased mean LOS in days (1.0, 95% CI: 0.9 - 1.2, p<0.001) and THC in USD (8217, 95% CI: 6940 - 9492, p<0.001). Independent predictors of readmission included female sex (Hazard Ratio [HR]: 1.14, 95% CI: 1.74 - 1.20, p<0.001), discharge against medical advice (HR: 1.54, 95% CI: 1.43 - 1.66, p<0.001), hypertension (HR: 1.28, 95% CI: 1.20 - 1.35, p<0.001), chronic kidney disease (HR: 1.13, 95% CI: 1.04 - 1.22, p<0.001) and anemia (HR: 1.42, 95% CI: 1.34 - 1.51, p<0.001). However, obesity (HR: 0.70, 95% CI: 0.62 - 0.79, p<0.001) and hyperlipidemia (HR: 0.92, 95% CI: 0.87 - 0.98, p=0.007) were associated with lower rate of readmission for DKA. Conclusion: About a fifth of T1DM patients hospitalized for DKA are readmitted within 30 days of discharge. A 30-day readmission following hospitalization for DKA is associated with higher inpatient mortality in this group. Hypertension, chronic kidney disease, and anemia are amongst the predictors of readmission in patients with DKA. However, comorbid obesity and hyperlipidemia were associated with lower rates of readmissions. Healthcare utilization costs are significantly higher in readmitted patients compared to index admissions for DKA. Efforts should be channeled towards identifying these predictors in hospitalized patients as well as proper discharge planning to decrease the burden of readmissions.
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A449
Open AccessRates and Predictors of 30-Day Readmission in Adults with Type 1 Diabetes Hospitalized for Diabetic Ketoacidosis in the US: A Nationwide Study
Introduction: Diabetic ketoacidosis (DKA) is an endocrinological emergency that may be associated with inpatient mortality. This hyperglycemic state is more common in type 1 diabetics (T1DM) as insulin deficiency promotes lipolysis and ketogenesis. Due to the difference in epidemiologic and comorbidity profiles between T1DM and other types of diabetes, it is important to investigate factors affecting this unique group. This study assessed the rate and predictors of readmission in adults with T1DM hospitalized for DKA. Methods: The National Readmission Database for 2017 was searched for hospitalizations involving persons 18 years or older with T1DM who were principally admitted for DKA from January 1 to November 30, 2017. Patients admitted electively or traumatic admissions were excluded from the analysis. Outcomes assessed were 30-day readmission rates, mortality, length of stay (LOS) and hospitalization charges (THC). Multivariate cox regression model was adapted to identify independent predictors of readmission. Results: A total of 91,625 hospitalizations involved adult with T1DM for DKA with 91,401 discharged alive. Of the patients discharged alive, the rate of 30-day readmission was 20.2%, involving 18,553 patients. A majority of patients had a principal readmission for DKA. Compared to the index admission, a 30-day readmission was associated with over two times the mortality rate (Risk ratio 2.06, 95% CI: 1.74 - 2.43, p<0.001). Readmission was associated with increased mean LOS in days (1.0, 95% CI: 0.9 - 1.2, p<0.001) and THC in USD (8217, 95% CI: 6940 - 9492, p<0.001). Independent predictors of readmission included female sex (Hazard Ratio [HR]: 1.14, 95% CI: 1.74 - 1.20, p<0.001), discharge against medical advice (HR: 1.54, 95% CI: 1.43 - 1.66, p<0.001), hypertension (HR: 1.28, 95% CI: 1.20 - 1.35, p<0.001), chronic kidney disease (HR: 1.13, 95% CI: 1.04 - 1.22, p<0.001) and anemia (HR: 1.42, 95% CI: 1.34 - 1.51, p<0.001). However, obesity (HR: 0.70, 95% CI: 0.62 - 0.79, p<0.001) and hyperlipidemia (HR: 0.92, 95% CI: 0.87 - 0.98, p=0.007) were associated with lower rate of readmission for DKA. Conclusion: About a fifth of T1DM patients hospitalized for DKA are readmitted within 30 days of discharge. A 30-day readmission following hospitalization for DKA is associated with higher inpatient mortality in this group. Hypertension, chronic kidney disease, and anemia are amongst the predictors of readmission in patients with DKA. However, comorbid obesity and hyperlipidemia were associated with lower rates of readmissions. Healthcare utilization costs are significantly higher in readmitted patients compared to index admissions for DKA. Efforts should be channeled towards identifying these predictors in hospitalized patients as well as proper discharge planning to decrease the burden of readmissions.
- Open Access
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A34-A35
Morbid Obesity Does Not Impact Mortality, Rate of Endoscopy in Patients With Biliary Acute Pancreatitis: A US Nationwide Analysis
Introduction: Morbid obesity (MO) is associated with increased mortality in various conditions including acute pancreatitis. Interventions are challenging in patients with MO due to higher prevalence of comorbidities that may affect airway and cardiopulmonary management. Biliary acute pancreatitis (BAP) is the most common etiology for acute pancreatitis in the US. Population-based studies on the effect of obesity on biliary acute pancreatitis are lacking. This study aimed to assess the impact of MO on outcomes of patients with BAP. Methods: Data was obtained from the Nationwide Inpatient Sample database for 2016 and 2017. Hospital discharges of patients 18 years and over with a principal diagnosis of BAP were included. This cohort was divided based on BMI into nonobese patients (BMI /=40.0). Patients with BMI between 30.0–39.9 were excluded. Primary outcome was inpatient mortality. Secondary outcomes included rate of endoscopic procedures, length of hospital stay (LOS), total hospital charges (THC), discharge diagnoses of hypocalcemia, septic shock, acute renal failure (AKI) and acute respiratory failure (ARF). Multivariate regression analysis was used to adjust for patients’ sociodemographic factors, Charlson comorbidity index as well as hospital characteristics as confounders. Results: A total of 128995 hospitalizations were principally for BAP, with 75.7% and 12.0% of these patients classified as nonobese and MO respectively. There was a significantly higher proportion of females (66.1 vs 54.5%, pConclusion: Even though we did not find any significative difference in mortality, patients with MO appear to have and increased LOS and THC, as well as more complications like septic shock, AKI, and hypocalcemia. This calls for a greater recognition of this association for further research studies and to recognize this potential association during clinical practice.
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A34-A35
Open AccessMorbid Obesity Does Not Impact Mortality, Rate of Endoscopy in Patients With Biliary Acute Pancreatitis: A US Nationwide Analysis
Introduction: Morbid obesity (MO) is associated with increased mortality in various conditions including acute pancreatitis. Interventions are challenging in patients with MO due to higher prevalence of comorbidities that may affect airway and cardiopulmonary management. Biliary acute pancreatitis (BAP) is the most common etiology for acute pancreatitis in the US. Population-based studies on the effect of obesity on biliary acute pancreatitis are lacking. This study aimed to assess the impact of MO on outcomes of patients with BAP. Methods: Data was obtained from the Nationwide Inpatient Sample database for 2016 and 2017. Hospital discharges of patients 18 years and over with a principal diagnosis of BAP were included. This cohort was divided based on BMI into nonobese patients (BMI /=40.0). Patients with BMI between 30.0–39.9 were excluded. Primary outcome was inpatient mortality. Secondary outcomes included rate of endoscopic procedures, length of hospital stay (LOS), total hospital charges (THC), discharge diagnoses of hypocalcemia, septic shock, acute renal failure (AKI) and acute respiratory failure (ARF). Multivariate regression analysis was used to adjust for patients’ sociodemographic factors, Charlson comorbidity index as well as hospital characteristics as confounders. Results: A total of 128995 hospitalizations were principally for BAP, with 75.7% and 12.0% of these patients classified as nonobese and MO respectively. There was a significantly higher proportion of females (66.1 vs 54.5%, pConclusion: Even though we did not find any significative difference in mortality, patients with MO appear to have and increased LOS and THC, as well as more complications like septic shock, AKI, and hypocalcemia. This calls for a greater recognition of this association for further research studies and to recognize this potential association during clinical practice.
- Open Access
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A22
Morbid Obesity Is Associated With Worse Outcomes and Increased Inpatient Mortality in Patients With Alcohol Induced Acute Pancreatitis
Introduction: The prevalence of obesity in the United States is rising. Obesity is a known comorbidity with various health impacts. Alcohol is a common etiology for acute pancreatitis. Obesity is known to be associated with liver dysfunction. It is unclear to what extent the degree of obesity affects patients with alcohol induced acute pancreatitis (AAP), as nationally representative data are lacking. This study aimed to ascertain the impact of morbid obesity on outcomes of patients with alcohol induced pancreatitis. Methods: Data was obtained from the Nationwide Inpatient Sample database for 2016 and 2017. Hospital discharges of patients 18 years and over with a principal diagnosis of AAP were included. This cohort was divided based on presence of comorbid obesity into nonobese patients, mild-moderately obese patients (MMO) (BMI: 30.0 - 39.9) and morbidly obese patients (MO) (BMI >/=40.0). Primary outcome was inpatient mortality. Secondary outcomes included length of hospital stay (LOS), total hospital charges (THC), discharge diagnoses of hypocalcemia, sepsis, acute renal failure (AKI) and acute respiratory failure (ARF). Multivariate regression analysis was used to adjust for patients’ sociodemographic factors, Charlson comorbidity index as well as hospital characteristics as confounders. Results: A total of 143650 hospitalizations were principally for AAP, with 5.5% and 2.7% of these patients classified as having MMO and MO, respectively. In MO patients, there was increased odds of mortality (aOR=2.99, 95% CI: 1.509 - 5.917, p=0.002) when compared with patients who were nonobese. There was no difference in mortality in patients with MMO (aOR 0.88 95% CI: 0.383 - 2.026, p=0.765) when compared with the nonobese group. MO patients had increased mean LOS of 1.1 days (95% CI: 0.7 - 1.6, p<0.001) as well as THC of $14481 (95% CI: 7894 - 21068, p<0.001), increased odds of hypocalcemia (aOR=1.77, 95% CI: 1.302 - 2.392, p<0.001), sepsis (aOR=1.84, 95% CI: 1.183 - 2.873, p=0.007), AKI (aOR=1.55, 95% CI: 1.257 - 1.912, p<0.001). Conclusion: Morbid obesity has a negative impact on outcomes of patients with AAP. Efforts should be channeled towards promoting alcohol cessation in at-risk patients as a preventative measure, as well as closer monitoring of hospitalized patients with morbid obesity to mitigated these adverse events.
- 1 May 2021
- Published by The Endocrine Society in Journal of the Endocrine Society
- Vol. 5 (Supplement) , A22
Open AccessMorbid Obesity Is Associated With Worse Outcomes and Increased Inpatient Mortality in Patients With Alcohol Induced Acute Pancreatitis
Introduction: The prevalence of obesity in the United States is rising. Obesity is a known comorbidity with various health impacts. Alcohol is a common etiology for acute pancreatitis. Obesity is known to be associated with liver dysfunction. It is unclear to what extent the degree of obesity affects patients with alcohol induced acute pancreatitis (AAP), as nationally representative data are lacking. This study aimed to ascertain the impact of morbid obesity on outcomes of patients with alcohol induced pancreatitis. Methods: Data was obtained from the Nationwide Inpatient Sample database for 2016 and 2017. Hospital discharges of patients 18 years and over with a principal diagnosis of AAP were included. This cohort was divided based on presence of comorbid obesity into nonobese patients, mild-moderately obese patients (MMO) (BMI: 30.0 - 39.9) and morbidly obese patients (MO) (BMI >/=40.0). Primary outcome was inpatient mortality. Secondary outcomes included length of hospital stay (LOS), total hospital charges (THC), discharge diagnoses of hypocalcemia, sepsis, acute renal failure (AKI) and acute respiratory failure (ARF). Multivariate regression analysis was used to adjust for patients’ sociodemographic factors, Charlson comorbidity index as well as hospital characteristics as confounders. Results: A total of 143650 hospitalizations were principally for AAP, with 5.5% and 2.7% of these patients classified as having MMO and MO, respectively. In MO patients, there was increased odds of mortality (aOR=2.99, 95% CI: 1.509 - 5.917, p=0.002) when compared with patients who were nonobese. There was no difference in mortality in patients with MMO (aOR 0.88 95% CI: 0.383 - 2.026, p=0.765) when compared with the nonobese group. MO patients had increased mean LOS of 1.1 days (95% CI: 0.7 - 1.6, p<0.001) as well as THC of $14481 (95% CI: 7894 - 21068, p<0.001), increased odds of hypocalcemia (aOR=1.77, 95% CI: 1.302 - 2.392, p<0.001), sepsis (aOR=1.84, 95% CI: 1.183 - 2.873, p=0.007), AKI (aOR=1.55, 95% CI: 1.257 - 1.912, p<0.001). Conclusion: Morbid obesity has a negative impact on outcomes of patients with AAP. Efforts should be channeled towards promoting alcohol cessation in at-risk patients as a preventative measure, as well as closer monitoring of hospitalized patients with morbid obesity to mitigated these adverse events.
- 1 April 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (5) , e9-e10
An Unusual Cause of Intermittent Abdominal Pain
- 1 April 2021
- Published by Elsevier in Gastroenterology
- Vol. 160 (5) , e9-e10
An Unusual Cause of Intermittent Abdominal Pain
- 1 March 2021
- Published by Elsevier in Thrombosis Research
- Vol. 199, 14-18
Predictors of venous thromboembolism in hospitalized patients with inflammatory bowel disease and colon cancer: A retrospective cohort study
- 1 March 2021
- Published by Elsevier in Thrombosis Research
- Vol. 199, 14-18
Predictors of venous thromboembolism in hospitalized patients with inflammatory bowel disease and colon cancer: A retrospective cohort study
- Open Access
- 1 January 2021
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 9
Massive Ischemic Strokes in a Young Patient With Severe Coronavirus Disease 2019 Pneumonia
Stroke is an identified sequela of severe coronavirus disease 2019 (COVID-19) infection. While the pathophysiology remains poorly understood, endothelial dysfunction and intravascular thrombosis secondary to sepsis-induced hypercoagulability likely increase the risk of stroke. This report describes the rare case of an otherwise healthy 42-year-old male who developed large bilateral ischemic infarcts during admission for severe hypoxemic respiratory failure secondary to COVID pneumonia. This report adds to scarce literature describing massive cerebrovascular injury in COVID patients and emphasizes the importance of increased clinical suspicion for stroke in patients who exhibit acute change in mental status or motor function, as well as rapid clinical deterioration.
- 1 January 2021
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 9
Open AccessMassive Ischemic Strokes in a Young Patient With Severe Coronavirus Disease 2019 Pneumonia
Stroke is an identified sequela of severe coronavirus disease 2019 (COVID-19) infection. While the pathophysiology remains poorly understood, endothelial dysfunction and intravascular thrombosis secondary to sepsis-induced hypercoagulability likely increase the risk of stroke. This report describes the rare case of an otherwise healthy 42-year-old male who developed large bilateral ischemic infarcts during admission for severe hypoxemic respiratory failure secondary to COVID pneumonia. This report adds to scarce literature describing massive cerebrovascular injury in COVID patients and emphasizes the importance of increased clinical suspicion for stroke in patients who exhibit acute change in mental status or motor function, as well as rapid clinical deterioration.
- 15 October 2020
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 36 (4) , 701-708
Temporal trend in inpatient mortality in inflammatory bowel disease-associated colorectal cancer vs non-inflammatory colorectal cancer: a nationwide retrospective study
Background Early detection and advancement in therapy have successfully achieved a steady decrease in colorectal cancer (CRC) mortality over the last two decades. On the other hand, studies investigating mortality trends in inflammatory bowel disease-associated CRC (IBD-CRC) are scarce and inconclusive. We conducted a retrospective analysis aiming to identify differences between inpatient mortality trends in IBD-CRC vs non-IBD-CRC and possible contributing factors. Methods The National Inpatient Sample (NIS) database from 2006-2014 was queried to identify all patients admitted with a diagnosis of CRC. The main outcome was the prevalence and trend of mortality among IBD-CRC and non-IBD-CRC. The secondary outcome was the evaluation of predictors of inpatient mortality. Results A total of 1,190,759 weighted cases with the admission diagnosis of CRC were included in the study. Of which 10,997 (0.9%) had a co-diagnosis of IBD. The population with non-IBD-CRC had a statistically significant downward temporal trend in mortality (p < 0.001), while patients with IBD-CRC did not have any statistically significant temporal trend in inpatient mortality (p = 0.067). After subgroup analysis, patients with Crohn’s disease-CRC had an upward temporal trend in mortality (p = 0.183) compared to patients with ulcerative colitis-CRC with a downward trend in mortality (p = 0.001). Sepsis resulted to be a stronger predictor of mortality for CD-CRC, while VTE for UC-CRC. Conclusion Multiples strategies established to prevent morbidity and mortality in CRC have been fruitful in non-IBD-CRC population, but have not been enough for IBD-CRC population to cause the same effect. Further strategies are needed to achieve a reduction in IBD-CRC mortality trend.
- 15 October 2020
- Published by Springer Nature in International Journal of Colorectal Disease
- Vol. 36 (4) , 701-708
Temporal trend in inpatient mortality in inflammatory bowel disease-associated colorectal cancer vs non-inflammatory colorectal cancer: a nationwide retrospective study
Background Early detection and advancement in therapy have successfully achieved a steady decrease in colorectal cancer (CRC) mortality over the last two decades. On the other hand, studies investigating mortality trends in inflammatory bowel disease-associated CRC (IBD-CRC) are scarce and inconclusive. We conducted a retrospective analysis aiming to identify differences between inpatient mortality trends in IBD-CRC vs non-IBD-CRC and possible contributing factors. Methods The National Inpatient Sample (NIS) database from 2006-2014 was queried to identify all patients admitted with a diagnosis of CRC. The main outcome was the prevalence and trend of mortality among IBD-CRC and non-IBD-CRC. The secondary outcome was the evaluation of predictors of inpatient mortality. Results A total of 1,190,759 weighted cases with the admission diagnosis of CRC were included in the study. Of which 10,997 (0.9%) had a co-diagnosis of IBD. The population with non-IBD-CRC had a statistically significant downward temporal trend in mortality (p < 0.001), while patients with IBD-CRC did not have any statistically significant temporal trend in inpatient mortality (p = 0.067). After subgroup analysis, patients with Crohn’s disease-CRC had an upward temporal trend in mortality (p = 0.183) compared to patients with ulcerative colitis-CRC with a downward trend in mortality (p = 0.001). Sepsis resulted to be a stronger predictor of mortality for CD-CRC, while VTE for UC-CRC. Conclusion Multiples strategies established to prevent morbidity and mortality in CRC have been fruitful in non-IBD-CRC population, but have not been enough for IBD-CRC population to cause the same effect. Further strategies are needed to achieve a reduction in IBD-CRC mortality trend.
- Open Access
- 17 September 2020
- Published by Springer Nature in Cureus
- Vol. 12 (9)
Secondary Abdominal Cocoon Syndrome Due To Chronic Beta-Blocker Use
Sclerosing encapsulating peritonitis (SEP), which is interchangeably used with the term "abdominal cocoon syndrome'', is a rare condition characterized by a thick fibrous membrane encasing portions of the intestinal wall leading to recurrent bowel obstructions. To date, literature describing the association between this condition and chronic beta-blocker therapy is scarce. This report adds by detailing a rare presentation of SEP and highlights an understudied yet important association of SEP with chronic beta-blocker therapy.
- 17 September 2020
- Published by Springer Nature in Cureus
- Vol. 12 (9)
Open AccessSecondary Abdominal Cocoon Syndrome Due To Chronic Beta-Blocker Use
Sclerosing encapsulating peritonitis (SEP), which is interchangeably used with the term "abdominal cocoon syndrome'', is a rare condition characterized by a thick fibrous membrane encasing portions of the intestinal wall leading to recurrent bowel obstructions. To date, literature describing the association between this condition and chronic beta-blocker therapy is scarce. This report adds by detailing a rare presentation of SEP and highlights an understudied yet important association of SEP with chronic beta-blocker therapy.